Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis — Toshifumi Tada (2022) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
Shared by
Masatoshi Kudo
Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis
Article
2022
en
Authors
+34 more
TT
Toshifumi Tada
TK
Takashi Kumada
AH
Atsushi Hiraoka
Abstract
1 min read
GPS can be used to predict survival in patients with unresectable HCC who were treated with lenvatinib.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Preprint
2021
C-Reactive Protein to Albumin Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Analysis
Toshifumi Tada
,
Takashi Kumada
,
Atsushi Hiraoka
,
Masashi Hirooka
,
Kazuya Kariyama
,
Joji Tani
,
Masanori Atsukawa
,
Koichi Takaguchi
,
Ei Itobayashi
,
Shinya Fukunishi
,
Kunihiko Tsuji
,
Toru Ishikawa
,
Kazuto Tajiri
,
Hironori Ochi
,
Satoshi Yasuda
,
Hidenori Toyoda
,
Takeshi Hatanaka
,
Satoru Kakizaki
,
Noritomo Shimada
,
Kazuhito Kawata
,
Takaaki Tanaka
,
Hideko Ohama
,
Kazuhiro Nouso
,
Asahiro Morishita
,
Akemi Tsutsui
,
Takuya Nagano
,
Norio Itokawa
,
Tomomi Okubo
,
Taeang Arai
,
Michitaka Imai
,
Atsushi Naganuma
,
Tomoko Aoki
,
Yohei Koizumi
,
Shinichiro Nakamura
,
Kouji Joko
,
Yoichi Hiasa
,
Masatoshi Kudo
Article
2022
C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Toshifumi Tada
,
Takashi Kumada
,
Atsushi Hiraoka
,
Masashi Hirooka
,
Kazuya Kariyama
,
Joji Tani
,
Masanori Atsukawa
,
Koichi Takaguchi
,
Ei Itobayashi
,
Shinya Fukunishi
,
Kunihiko Tsuji
,
Toru Ishikawa
,
Kazuto Tajiri
,
Hironori Ochi
,
Satoshi Yasuda
,
Hidenori Toyoda
,
Takeshi Hatanaka
,
Satoru Kakizaki
,
Noritomo Shimada
,
Kazuhito Kawata
,
Takaaki Tanaka
,
Hideko Ohama
,
Kazuhiro Nouso
,
Article
2020
Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
Tomoko Aoki
,
Masatoshi Kudo
,
Kazuomi Ueshima
,
Masahiro Morita
,
Hirokazu Chishina
,
Masahiro Takita
,
Satoru Hagiwara
,
Hiroshi Ida
,
Yasunori Minami
,
Masakatsu Tsurusaki
,
Naoshi Nishida
Dataset
Supplementary Material for: Nutritional Index as Prognostic Indicator in Patients Receiving Lenvatinib Treatment for Unresectable Hepatocellular Carcinoma
Atsushi Hiraoka
,
Takashi Kumada
,
Toshifumi Tada
,
Shinya Fukunishi
,
Masanori Atsukawa
,
Masashi Hirooka
,
Kunihiro Tsuji
,
Toru Ishikawa
,
Koichi Takaguchi
,
Kazuya Kariyama
,
Ei Itobayashi
,
Kazuto Tajiri
,
Naohiko Shimada
,
Hiroshi Shibata
,
Hironori Ochi
,
Kazuhito Kawata
,
Hideki Toyoda
,
Hideko Ohama
,
Akemi Tsutsui
,
Norio Itokawa
,
Koremasa Hayama
,
T. Arai
,
Michitaka Imai
,
,
Article
2023
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.
Margherita Rimini
,
Andrea Casadei‐Gardini
,
Mara Persano
,
Toshifumi Tada
,
Goki Suda
,
Shigeo Shimose
,
Masatoshi Kudo
,
Jaekyung Cheon
,
Fabian Finkelmeier
,
Lorenza Rimassa
,
José Presa
,
Gianluca Masi
,
Changhoon Yoo
,
Sara Lonardi
,
Francesco Tovoli
,
Mario Scartozzi
,
Valentina Burgio
,
Stefano Cascinu
,
Alessandro Cucchetti
Asahiro Morishita
,
Akemi Tsutsui
,
Takuya Nagano
,
Norio Itokawa
,
Tomomi Okubo
,
Taeang Arai
,
Michitaka Imai
,
Atsushi Naganuma
,
Tomoko Aoki
,
Yohei Koizumi
,
Shinichiro Nakamura
,
Kouji Joko
,
Yoichi Hiasa
,
Masatoshi Kudo
Shinichiro Nakamura
Kojiro Michitaka
,
Yoichi Hiasa
,
Masatoshi Kudo
,
Real-Life Practice Experts For HCC Study Group And HCC Group
Discussion(0)
No comments yet. Be the first to comment.